| Literature DB >> 16508892 |
G Gründer1, M Kungel, M Ebrecht, T Göröcs, S Modell.
Abstract
Aripiprazole is the first approved atypical antipsychotic with a mechanism of action that exerts a partial agonism with high affinity at Dopamin D2- and Serotonin-5-HT1A-receptors as well as an antagonism at Serotonin-5-HT2A-receptors. Aripiprazole provides good clinical effectiveness and a favorable profile of safety and tolerability. The special pharmacodynamics of aripiprazole are described herein.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16508892 DOI： 10.1055/s-2006-931485
Source DB: PubMed Journal: Pharmacopsychiatry ISSN： 0176-3679 Impact factor: 5.788